Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8α+ dendritic cells and reduces experimental acute graft-versus-host disease

Blood

Volumn 99, Issue 5, 2002, Pages 1825-1832

  Teshima, Takanori ^a,b   Reddy, Pavan ^a,b   Lowler, Kathleen P ^a,b   Kukuruga, Mark A ^a,b   Liu, Chen ^a,b   Cooke, Kenneth R ^a,b   Ferrara, James L M ^a,b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FLT3 LIGAND;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE AMPLIFICATION; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; IN VITRO STUDY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0036493605     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1825     Document Type: Article

References (50)

1. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations
2. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells
3. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs
4. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand treated mice: Multiple dendritic cell subpopulation identified
5. Modulating the immune response with dendritic cells and their growth factors
6. Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity
7. Flt3 ligand induces tumor regression and antitumor immune responses in vivo
8. Donor pretreatment with Flt-3 ligand augments antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities within liver allografts and alters the pattern of intragraft apoptotic activity
9. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant
10. Flt-3 ligand increases microchimerism but can prevent the therapeutic effect of donor bone marrow in transiently immunosuppressed cardiac allograft recipients
11. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: Modulation by tacrolimus
12. II-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance
13. Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice
14. Flt3 ligand pretreatment promotes protective immunity to Listeria monocytogenes
15. Expanding dendritic cells in vivo enhances the induction of oral tolerance
16. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis
17. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production
18. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen
19. High levels of a major histocompatibility complex II self-peptide complex on dendritic cells from the T cell areas of lymph nodes
20. Comparative analysis of murine dendritic cells derived from spleen and bone marrow
21. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation
22. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice
23. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: The roles of minor H antigens and endotoxin
24. Host reactive donor T cells are associated with lung injury after experimental allogenic bone marrow transplantation
25. Induction of interleukin 10-producing, non-proliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
26. Differentiation of T regulatory cells by immature dendritic cells
27. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro
28. Dendritic cell subtypes in mouse lymphoid organs: Cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes
29. The veto phenomenon in T-cell regulation
30. Developmental pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice
31. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas
32. CD8alpha+ and CD8alpha-subclasses of dendritic cells direct the development of distinct T helper cells in vivo
33. Are CD8+ dendritic cells (DC) veto cells? The role of CD8 on DC in DC development and in the regulation of CD4 and CD8 T cell responses
34. Differential regulation of T-cell proliferation and apoptosis by hepatic CD8alpha(+)(lymphoid-related) and CD8alpha(-)(myeloid) dendritic cells
35. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12
36. Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion
37. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: Implications for anti-cancer and anti-viral therapy
38. Phenotypic and functional characterization of mouse hepatic CD8 alpha+ lymphoid-related dendritic cells
39. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo
40. RelB is essential for the development of myeloid-related CD8alpha - Dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells
41. IL-12 acts selectively on CD8 alpha-dendritic cells to enhance presentation of a tumor peptide in vivo
42. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
43. Pathogenesis and prevention of graft-versus-host disease
44. Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality
45. Dendritic cells in transplantation - Friend or foe?
46. CD8+TCR+ and CD8+TCR - Cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers
47. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand
48. The development, maturation, and turnover rate of mouse spleen dendritic cell populations
49. The benefits of an alloresponse: Graft-versus-tumor
50. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation